US FDA accepts Roche's re-submission for Actemra
This article was originally published in Scrip
Executive Summary
The US FDA has accepted the resubmission of the BLA for Roche's first-in-class interleukin-6 (IL-6) inhibitor Actemra (tocilizumab) for the treatment of rheumatoid arthritis.